Identification of Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease Subgroups by Machine Learning Implementation in Electronic Health Records.
Li H, Huston J, Zielonka J, Kay S, Sauler M, Gomez J. Identification of Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease Subgroups by Machine Learning Implementation in Electronic Health Records. Chronic Obstructive Pulmonary Diseases Journal Of The COPD Foundation 2024 PMID: 39423339, DOI: 10.15326/jcopdf.2024.0556.Peer-Reviewed Original ResearchElectronic health recordsMachine learningAcute exacerbation of COPDAdoption of electronic health recordsHealth recordsMachine learning implementationElectronic health record dataImplementation of MLEHR-derived dataML implementationChronic obstructive pulmonary disease subgroupCOVID-19 cohortSevere acute exacerbation of COPDClinical careExacerbation of COPDAcute exacerbationRetrospective cohort of patientsLearning implementationSeverity of acute exacerbations of COPDMachineRelevant subgroupsRetrospective cohortImplementationCohortCohort of patientsToll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.
Trujillo G, Regueiro-Ren A, Liu C, Hu B, Sun Y, Ahangari F, Fiorini V, Ishikawa G, Al Jumaily K, Khoury J, McGovern J, Lee C, Peng X, Pivarnik T, Sun H, Walia A, Woo S, Yu S, Antin-Ozerkis D, Sauler M, Kaminski N, Herzog E, Ryu C. Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2024 PMID: 39189851, DOI: 10.1164/rccm.202401-0065oc.Peer-Reviewed Original ResearchToll-like receptor 9Model of pulmonary fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisFibroproliferative responseLung diseaseIdiopathic pulmonary fibrosis cohortsExpression of toll-like receptor 9Toll-like receptor 9 activationTransplant-free survivalExpression of MCP-1Cohort of patientsSlow clinical progressionFibrotic lung diseaseAccelerated disease courseFatal lung diseaseIP-10Pharmacodynamic endpointsPreclinical modelsDisease courseClinical progressionPlasma mtDNAMCP-1Receptor 9Mouse model